

- Accelerator mass spectrometry 66
 Accuracy of diagnostics 107
 Acetylcholinesterase inhibition 202
 – inhibitor(s) 299, 314
 Activities of daily living 202
 Aging 36, 90
 Alcohol-associated dementia 119
 Aluminium, isotopic 66
 Alzheimer's disease 1, 11, 17, 25, 29, 36,
 53, 66, 81, 90, 100, 107, 139, 147, 153,
 181, 187, 197, 212, 230, 239, 275, 286,
 299, 314, 322, 327, 342
 – –, sporadic 245
 – – subtypes 212
 'Amyloid cascade hypothesis' 187
 β-Amyloid 181, 239
 – deposition 187
 α₁-Antichymotrypsin 239
 Antiphospholipid antibodies 36
 Apolipoprotein E 25, 29, 181, 239
 – – genotype 70
 Astrocyte 251
 Attention 327, 342
- Behavior 202
 Behavioral changes 294
 – and psychological symptoms of
 dementia 147
 Binswanger's disease 161
 Blood-brain barrier 263
 Brain 123
- Cardiolipin 36
 Central nervous system 1
 CERAD 107
 Cerebral cortex 336
 Cerebrospinal fluid 322
 Cholesterol 181
 Cholinergic function 29
 Circadian rhythms 90
 Clinical trial 202
 Cognition 1, 46, 81, 202
 Cognitive function 166
 Computed tomography 81
 Contrast enhancement 263
 Controlled processes 46
 Copper 251
 Correlates of persistence 147
 Corticobasal degeneration 139
 Cortisol 90
 CT scans 114
- Dehydroepiandrosterone sulfate 90
 Delta power 327
 Dementia 1, 36, 39, 46, 70, 90, 114,
 153, 166, 176, 193, 202, 223, 230,
 294
 –, Alzheimer type 268
 –, vascular 36, 59, 119, 135, 161, 239,
 268, 275, 294, 322
 – –, pathology 197
 – with Lewy bodies 187, 219, 327
 Depression 59
 Detection 223
 Diagnosis 114
 Donepezil 299
 Driving 153
- EEG, multichannel 39
 –, quantitative 29
 Efficacy 202
 EGb 761® 230
 Elderly 166
 Electroencephalography 81
 Emotional recognition 268
 Episodic memory 100, 342, 351
 Eptastigmine 17
 Estrogen(s) 1
 – receptor 119
 Event-related potential paradigm 39
- Famous faces 336
 First symptoms 286
 Fluctuating cognition 327
 Frontotemporal dementia 100, 123, 275,
 286
- Gastrointestinal absorption 66
 Gender 25
 General cognitive dysfunction 53
 Geriatric Evaluation by Relative's Rating
 Instrument 230
Ginkgo biloba 230
 Global function 202
 Glucose 176
- Histopathology 123
 Human brain(s) 181, 245
- Identification 336
 Immunoblotting 251
 Immunohistochemistry 251
 Insulin 176
 – resistance 176
- Intellectual impairment 39
 Intronic polymorphism 239
- Lacunar infarctions 161
 Late-onset Alzheimer's disease 119
 Lewy body disease 314
 Lipids 70
 Lipoprotein(a) 135
 – phenotype 135
 Longitudinal evaluation 147
- Magnetic resonance imaging 90, 123,
 263
 Mattis Dementia Rating Scale 314
 Membrane alterations 181
 Memory 74
 Metallothionein 251
 Microinfarction 59
 Mini Mental State Examination 166,
 193
 mRNA 245
- Naming 336
 Neuropathology 336
 Neuropsychiatric inventory 294
 Neurotoxicity 181
 NINCDS/ADRDA 107, 342
 Nitric oxide 322
 Non-demented patients 187
- Pain 11
 Parkinsonism 219, 314
 Parkinson's disease 39
 Pathogenesis 197
 Placebo-controlled trials 17
 Polymorphism 119
 Population study, longitudinal 166
 Positron emission tomography 139
 Preclinical deficits 46
 Predictive factors 212
 Presenilin 1 239, 245
 Prevalence 223
 Prevention 1
 Primary care 223
 – degenerative dementia 36
 Principal component analysis 74
 Prion disease 251
 – protein 251
 Progression 219
- Questionnaire 11

Randomized controlled trial 230
Receiver-operating characteristic analysis
74, 193
Recent memory impairment 53
Regional cerebral blood flow 81, 275
Reliability 107
Remote memory 100
– – impairment 53
Retrieval support 351

Schema 351
Screening 74
– test 193

Selective reminding procedure 74
Semantic memory 100, 342
Serum α_1 -antichymotrypsin 25
Short-Memory Questionnaire 193
Single-photon emission (computed) tomog-
raphy 153, 275
Skin fibroblasts 245
Subcortical white matter dementia 275
Systemic effect 197

Tacrine (Cognex) 314
Temporal gradient 53
– lobe 187
Treatment 1

Validity 74
Variability 327
Volumetry 90

White matter 123
– – lacunar dementia 294
– – lesions 161, 263